This month Rita Numerof assesses the successes that the FDA’s Breakthrough Therapy Designation has enjoyed to date and explains what this fledgling submission process means for pharmaceutical market access.
Warren Buffett once said, "Intrinsic value is the only logical way to (manage) investments and businesses." It provides the strongest foundation to the enduring growth of companies.
by Graham Young
It’s a somewhat contentious – tendentious even – title. So much so in fact, that I’ve been asked once again to stress that these are my opinions and not eyeforpharma’s. But I would like to examine the case for and against the Procurement Manager in the modern pharmaceutical industry.
by David Laws
David Laws examines today’s industry trend of offering services ‘Beyond the Pill’. In the first installment, David looks at the intent and objective of such services and asks, who really benefits from all of these value adds?
Medication adherence is on the radar more than ever before, so it’s important to understand the basics of how adherence is typically measured and the shortcomings of these measurements.
by Ifti Ahmed
This month Ifti examines one of the key drivers in sales success – Motivation, and explains how to properly motivate a sales team to achieve your objectives.
Mary Assimakopoulos examines a common yet often unaddressed patient concern – the very human fear of needles!
While the pharmaceutical industry has found itself in a turbulent healthcare marketplace rife with changing regulations, new competitive challenges, and increasing pricing pressures, the end goal for manufacturers remains the same -- product reimbursement and optimal pricing.
Things are not what they used to be. In the good old days you could launch a drug and enjoy around seven years to reach peak sales. However, now the window is shorter and typically less than five years.
For the pharmaceutical rep, is the goal of patient retention in conflict with the more traditional goal of patient acquisition? Patient acquisition primarily demands a focus on the prescribing physician, whereas patient retention demands a focus on the patient. Is there even time for both?
by Ifti Ahmed
This month, Ifti Ahmed examines that age-old, often intimidating reality of any sales role - objections, and provides insights into how that 'no' could just be another opportunity for a 'yes'.
Dr Andree Bates explains while detailed analytics are imperative for sales and marketing.
What could motivate patients to show more concern for their pet’s health and medication adherence than their own? Katrina Firlik, MD examines the impact that caring for others can have on caring for yourself…
by Jeff Elton
Jeff Elton explains how the need for more targeted, personalized therapies, are requiring changes throughout the drug development process, and how best your company can adapt.
by Ifti Ahmed
“I like your product, but it’s too expensive!” How many times has a sales person heard these words and felt trapped? The price or financial component is very important and can mean the difference between a sale or an almost sale – depending on how you approach it of course.
This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.
As payers and providers consolidate and use their market share to enhance negotiations with manufacturers, what can pharma do to protect their business and capture value for their products? This month, I explore the serious implications associated with this trend of healthcare consolidation.
Social media is ever-changing. In reality it’s the community ideals behind blogs, Facebook, podcasts, text messaging, micro-blogging and more, that are fundamental. The cool tools will evolve, change and disappear, but those ideals will always remain.